Hummingbird Diagnostics Gmbh

Comprehensive Biomarker Center Gmbh

Siemens Aktiengesellschaft

Universität Des Saarlandes

Siemens Healthcare Gmbh

Siemens Ag Osterreich

Siemens Healthcare Diagnostics Gmbh

Biomerieux, Inc.

Siemens Healthcare Diagnostics Products Gmbh

Nycomed Gmbh

Ares Genetics Gmbh

Siemens Healthcare Diagnostics Holding Gmbh

Andreas Keller

Markus Beier

Eckart Meese

Petra Leidinger

Anne Borries

Christina Backes

Peer Friedrich Staehler

Cord Friedrich Stähler

Anke Wendschlag

Andreas Kappel

Hugo Katus

Benjamin Meder

Jan Kirsten

Matthias Scheffler

Dorin Comaniciu

Bogdan Georgescu

Ali Kamen

Tommaso Mansi

Herbert Schwarz

Peer Friedrich Stähler

Xudong Zheng

Patrick Küry

William D Bedzyk

Wilhelm Wurst

Hans-Peter Hartung

Daniel Sickert

Susanne Schmolke

Wolfgang Rottbauer

Andreas Emanuel Posch

Thomas Brefort

Britta Vogel

Peer F Stähler

Thomas Laufer

Mustafa Kahraman

Cord Friedrich Stahler

Orhan Aktas

Michaela Wicke

Jens Ingwersen

Timour Prozorovski

Wei Keat Lim

Vanessa King

Andreas Kremer

Cord Friedrich Staehler

Emil Wirsz

Valentina Galata

Gabriel Rensen

Linda Marie Anderson-Mauser

Valesca Boisguerin

Dietrich Hafner

Frank Rathgeb

Christoph Karl

Peter Schaffer

Hugo A Katus

Patrick FRÖSE

Peer Stähler

Jochen Kohlhaas

Anne RÖSKE

Anke Booker

Ian Wright

Eckhart Meese

The present invention relates to a method of removing an RNA fraction with &#x2265;200 nucleotides in length from a whole blood sample. The present invention also relates to a method of purifying an RNA fraction with &#x3c;200 nucleotides in length from a whole blood sample. The present invention further relates to a method of determining the level of RNA molecules with &#x3c;200 nucleotides in length. In addition, the present invention relates to a method for diagnosing a disease in an individual. Moreover, the present invention relates to a kit which is useful for carrying out the methods of the present invention.

Purification of RNA fractions using a hydrophilic polymeric material

The invention relates to methods for diagnosing Parkinson's Disease PAD) with miRNA markers. Towards the identification of biomarkers for diagnosis of PD, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified.

Diagnostic MiRNA markers for Parkinson's disease

The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject.

Complex sets of miRNAs as non-invasive biomarkers for dilated cardiomyopathy

The invention relates to novel miRNA markers useful for diagnosis or therapy of disease, in particular for neuronal disorders such as Alzheimer's Disease (AD).

MiRNAs as diagnostic markers

The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The present invention also relates to a method of identifying a compound suitable for the treatment of multiple sclerosis in a patient. Further, the present invention relates to the use of a polynucleotide or a polynucleotide set for detecting a miRNA to determine whether a patient responds to a therapeutic treatment of multiple sclerosis, to monitor the course of multiple sclerosis in a patient, to determine the risk of a relapse of multiple sclerosis in a patient, to adjust the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, and to identify a compound suitable for the treatment of multiple sclerosis in a patient. Furthermore, the present invention relates to a kit for determining whether a patient responds to a therapeutic treatment of multiple sclerosis, for monitoring the course of multiple sclerosis in a patient, for determining the risk of a relapse of multiple sclerosis in a patient, for adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, or for identifying a compound suitable for the treatment of multiple sclerosis in a patient comprising means for determining the level of at least one miRNA in a test sample isolated from a patient.

MiRNA based treatment monitoring in multiple sclerosis

A system operating in a plurality of modes to provide an integrated analysis of molecular data, imaging data, and clinical data associated with a patient includes a multi-scale model, a molecular model, and a linking component. The multi-scale model is configured to generate one or more estimated multi-scale parameters based on the clinical data and the imaging data when the system operates in a first mode, and generate a model of organ functionality based on one or more inferred multi-scale parameters when the system operates in a second mode. The molecular model is configured to generate one or more first molecular findings based on a molecular network analysis of the molecular data, wherein the molecular model is constrained by the estimated parameters when the system operates in the first mode. The linking component, which is operably coupled to the multi-scale model and the molecular model, is configured to transfer the estimated multi-scale parameters from the multi-scale model to the molecular model when the system operates in the first mode, and generate, using a machine learning process, the inferred multi-scale parameters based on the molecular findings when the system operates in the second mode.

System and methods for integrated and predictive analysis of molecular, imaging, and clinical data for patient-specific management of diseases

The invention relates to methods for diagnosing multiple sclerosis with miRNA markers. Diagnosis of multiple sclerosis (MS) can be challenging in patients with atypical presentations and during a first neurological deficit possibly related to inflammatory demyelination. Towards the identification of biomarkers for diagnosis of MS, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified, which have previously not been related to MS according to the microRNA disease database. These miRNAs could potentially serve as future diagnostic biomarkers for MS and help in diagnosis, monitoring disease activity, and evaluation of treatment responses in patients with MS.

Diagnostic miRNA profiles in multiple sclerosis

The invention relates to methods for diagnosing Alzheimer's Disease (AD) with miRNA markers. Diagnosis of AD Towards the identification of biomarkers for diagnosis of AD, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified.

Diagnostic miRNA markers for Alzheimer

Diagnostic miRNA markers for Parkinson disease

The present invention provides novel methods for diagnosing diseases based on the determination of specific miRNAs that have altered expression levels in disease states compared to healthy controls.

MiRNA fingerprint in the diagnosis of multiple sclerosis

The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.

miRNA in the diagnosis of ovarian cancer

The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject.

Complex sets of miRNAs as non-invasive biomarkers for kidney cancer

miRNA fingerprint in the diagnosis of lung cancer

MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing prostate cancer based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.

MiRNA fingerprint in the diagnosis of prostate cancer

miRNA fingerprint in the diagnosis of diseases

Growing community of inventors

Püttlingen, Germany

Andreas Keller